Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Inv. presentation Acq. announced Consulting agrmnt
|
Enliven Therapeutics, Inc. (IMRA)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/03/2023 |
4
| Lyssikatos Joseph P (Chief Scientific Officer) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Sold 12,000 shares
@ $13.6248, valued at
$163.5k
Exercised 12,000 options to buy
@ $1.12, valued at
$13.4k
|
|
09/28/2023 |
4
| 5AM Partners VI, LLC (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Sold 164,789 shares
@ $15, valued at
$2.5M
Sold 32,711 shares
@ $15, valued at
$490.7k
|
|
09/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/19/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Exercised 2,125 options to buy
@ $4.28, valued at
$9.1k
|
|
05/19/2023 |
4
| Gupta Rishi (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Exercised 2,125 options to buy
@ $4.28, valued at
$9.1k
|
|
02/27/2023 |
4
| Schwab Andrew J. (Director) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 4,838,092 shares
@ $0 Granted 960,383 shares
@ $0 |
|
02/27/2023 |
4
| Heyman Richard A. (Director) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 149,820 shares
@ $0 Granted 37,407 shares
@ $0 Granted 31,172 shares
@ $0 Granted 20,657 options to buy
@ $2.48, valued at
$51.2k
|
|
02/27/2023 |
4
| Gupta Rishi (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 7,611,458 shares
@ $0 Granted 288,114 shares
@ $0 |
|
02/27/2023 |
4
| Bauer Jake (Director) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 87,372 shares
@ $0 Granted 17,706 options
@ $2.48, valued at
$43.9k
|
|
02/27/2023 |
4
| Derynck Mika K (Director) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 87,373 options to buy
@ $2.48, valued at
$216.7k
|
|
02/27/2023 |
4
| Patel Anish (COO) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 36,722 shares
@ $0 Granted 394,027 shares
@ $0 Granted 10,767 options to buy
@ $1.12, valued at
$12.1k
Granted 2,827 options to buy
@ $2.48, valued at
$7k
Granted 75,620 options to buy
@ $2.48, valued at
$187.5k
|
|
02/27/2023 |
4
| Lyssikatos Joseph P (Chief Scientific Officer) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 1,117,035 shares
@ $0 Granted 344,550 options to buy
@ $1.12, valued at
$385.9k
Granted 88,531 options to buy
@ $2.48, valued at
$219.6k
|
|
02/27/2023 |
4
| Hohl Benjamin (CFO) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 262,120 options to buy
@ $2.48, valued at
$650.1k
|
|
02/27/2023 |
4
| Kintz Samuel (President and CEO) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 1,087,525 shares
@ $0 Granted 88,531 shares
@ $0 Granted 88,531 shares
@ $0 Granted 344,550 options to buy
@ $1.12, valued at
$385.9k
Granted 404,363 options to buy
@ $2.48, valued at
$1M
|
|
02/27/2023 |
4
| Collins Helen Louise (Chief Medical Officer) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 287,084 options to buy
@ $2.48, valued at
$712k
|
|
02/27/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 7,611,458 shares
@ $0 Granted 288,114 shares
@ $0 |
|
02/27/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Bought 622 shares
@ $22.072, valued at
$13.7k
Acquired 729,891 shares
@ $0 |
|
02/27/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (Former 10% owner) has filed a Form 4 on Enliven Therapeutics, Inc.
Txns:
| Granted 1,152,460 shares
@ $0 |
|
02/23/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on IMARA Inc.
Txns:
| Bought 8,194 shares
@ $5.249, valued at
$43k
Bought 23,565 shares
@ $5.113, valued at
$120.5k
|
|
02/22/2023 |
4
| GRAY MICHAEL (CFO & COO) has filed a Form 4 on IMARA Inc.
Txns:
| Sold 9,856 shares
@ $4.67, valued at
$46k
|
|
02/22/2023 |
4
| Ballal Rahul D. (CEO) has filed a Form 4 on IMARA Inc.
Txns:
| Sold 32,861 shares
@ $4.66, valued at
$153.1k
|
|
02/01/2023 |
4
| GRAY MICHAEL (CFO & COO) has filed a Form 4 on IMARA Inc.
Txns:
| Sold 3,596 shares
@ $3.92, valued at
$14.1k
|
|
02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|